The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
RECIST
immunotherapy
irRECIST
metastasis
renal cell carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Aug 2019
30 Aug 2019
Historique:
received:
05
08
2019
revised:
28
08
2019
accepted:
28
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
22
1
2020
Statut:
epublish
Résumé
Immunotherapy has changed the therapeutic scenario of metastatic renal cell carcinoma (mRCC), however the evaluation of disease response to immune-checkpoint inhibitors is still an open challenge. Response evaluation criteria in solid tumors (RECIST) 1.1 criteria are the cornerstone of response assessment to anti-neoplastic treatments, but the use of anti-programmed death receptor 1 (PD1) and other immunotherapeutic agents has shown atypical patterns of response such as pseudoprogression. Therefore, immune-modified criteria have been developed in order to more accurately categorize the disease response, even though their use in the everyday clinical practice is still limited. In this review we summarize the available evidence on this topic, with particular focus on the application of immune-modified criteria in the setting of mRCC.
Identifiants
pubmed: 31480348
pii: ijms20174263
doi: 10.3390/ijms20174263
pmc: PMC6747319
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
J Immunother. 2007 Nov-Dec;30(8):825-30
pubmed: 18049334
Cancer Immun. 2008 Jan 17;8:1
pubmed: 18198818
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10
pubmed: 18287062
J Natl Cancer Inst. 2008 Sep 17;100(18):1280-1
pubmed: 18780859
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Immunol. 2009 Nov;10(11):1185-92
pubmed: 19783989
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Ann Oncol. 2010 Oct;21(10):1944-51
pubmed: 20237004
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
Eur Urol. 2015 Jan;67(1):100-110
pubmed: 24841777
J Immunother Cancer. 2014 Jun 18;2:17
pubmed: 24991412
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Eur J Radiol. 2015 Jul;84(7):1259-68
pubmed: 25937524
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancer Immunol Res. 2016 Jan;4(1):12-7
pubmed: 26589768
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
JAMA Oncol. 2016 Sep 1;2(9):1179-86
pubmed: 27243803
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
J Immunother Cancer. 2016 Jun 21;4:30
pubmed: 27330803
Expert Opin Biol Ther. 2016 Oct;16(10):1265-75
pubmed: 27434205
Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1089-96
pubmed: 27450183
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Eur Urol. 2017 Dec;72(6):962-971
pubmed: 28262413
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Eur J Cancer. 2017 May;77:165-167
pubmed: 28385325
Semin Oncol. 2017 Feb;44(1):3-7
pubmed: 28395760
Eur Urol. 2017 Sep;72(3):368-376
pubmed: 28410865
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
JAMA Oncol. 2017 Nov 1;3(11):1473-1474
pubmed: 28662228
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1395-1402
pubmed: 28956645
Curr Opin Urol. 2018 Jan;28(1):35-41
pubmed: 29083998
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
J Clin Oncol. 2018 Mar 20;36(9):850-858
pubmed: 29341833
Clin Genitourin Cancer. 2018 Aug;16(4):e735-e742
pubmed: 29478961
World J Urol. 2018 Nov;36(11):1703-1709
pubmed: 29549485
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
N Engl J Med. 2018 Aug 30;379(9):e14
pubmed: 30157404
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Int J Mol Sci. 2019 Apr 04;20(7):null
pubmed: 30987368
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Expert Opin Biol Ther. 2019 Aug 6;:1-4
pubmed: 31369337
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
J Exp Med. 1995 Aug 1;182(2):459-65
pubmed: 7543139